Retrophin Reports First Quarter 2017 Financial Results
Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS First quarter revenues rose 16 percent to $34 million SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. ( …